Shares of Giant Biogene (02367) rose more than 8% during the trading session. At the time of writing, the stock was up 7.03%, trading at HK$34.4, with a turnover of HK$256 million. The surge follows the company's recent announcement that its Class III medical device, the "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution," has received regulatory approval. This product is the world's first implantable solution of recombinant collagen and sodium hyaluronate approved for improving smoothness in the cheek area, having passed a joint review by medical device and pharmaceutical regulatory authorities. CICC expressed a positive outlook, stating that the approval of this product will further expand the company's aesthetic medicine portfolio, demonstrating its leading technological research and development capabilities. Looking at the medium to long term, the institution believes the company's R&D strength, brand recognition, and team cohesion remain solid. It suggests monitoring opportunities for strategic positioning as the core cosmetics business recovers and the aesthetics segment contributes incremental growth.